---
layout: post
title: "PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results"
date: 2026-02-19T21:01:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302693077.html
significance: 8.00
---

<p>– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302693077.html)

**Published:** 2026-02-19 21:01:00 +0000

**Significance Score:** 8.00

[View original](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302693077.html)
